Bottom line
PRHSX vs HGHAX: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and HGHAX (The Hartford Healthcare Fund) share a meaningful slice of their top holdings — about 65% by weight.
But PRHSX is far broader, holding 279 positions to 80 for HGHAX, so beyond the top names it adds exposure HGHAX doesn't have.
PRHSX is cheaper at 0.83% vs 1.33% — a difference of $50 a year per $10,000 invested.
HGHAX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
PRHSX vs HGHAX side by side
| PRHSX | HGHAX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | T. Rowe Price | Hartford |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 1.33% |
| Annual cost per $10k | $83 | $133 |
| 10-yr cost on $10k (prospectus) | $1,025 | $2,063 |
| Max front load | — | 5.5% |
| 12b-1 fee | — | 0.25% |
| 1-yr return | +17.7% | — |
| 5-yr return (annualized) | +4.2% | — |
| 10-yr return (annualized) | +9.1% | — |
| Best quarter | +23.5% | +20.9% |
| Worst quarter | −15.8% | −15.7% |
| Net assets (fund) | $11.9B | $772.2M |
| Number of holdings | 279 | 80 |
| Portfolio turnover | 62% | 49% |
| Returns as of | Dec 31, 2025 | — |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | HGHAX | Difference |
|---|---|---|---|
| 2025 | +17.7% | +15.6% | +2.1% |
| 2024 | +1.8% | 0.0% | +1.8% |
| 2023 | +3.1% | +3.8% | −0.7% |
| 2022 | −12.2% | −11.7% | −0.5% |
| 2021 | +13.3% | +10.0% | +3.3% |
| 2020 | +30.1% | +22.6% | +7.5% |
| 2019 | +29.1% | +33.3% | −4.2% |
| 2018 | +1.2% | −3.0% | +4.2% |
| 2017 | +28.0% | +21.6% | +6.4% |
| 2016 | −10.4% | −8.6% | −1.8% |
Source: Fund prospectus bar charts
Holdings overlap
14 of PRHSX's top 25 holdings also appear in HGHAX's top 25.
| Holding | PRHSX | HGHAX |
|---|---|---|
| Eli Lilly & Co | 14.28% | 12.03% |
| Johnson & Johnson | 6.63% | 6.75% |
| Unitedhealth Group Inc | 5.99% | 4.74% |
| Abbvie Inc | 5.10% | 4.21% |
| Merck & Co. Inc. | 4.01% | 6.00% |
| Thermo Fisher Scientific Inc | 2.52% | 1.58% |
| Vertex Pharmaceuticals Inc | 2.28% | 2.64% |
| Abbott Laboratories | 1.89% | 1.82% |
| Intuitive Surgical Inc | 1.87% | 2.88% |
| Amgen Inc | 1.82% | 1.39% |
| Stryker Corp | 1.78% | 1.24% |
| Elevance Health Inc | 1.53% | 3.00% |
| Danaher Corp | 1.43% | 2.57% |
| Cvs Health Corp | 0.94% | 2.84% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
HGHAX top 10
- Eli Lilly & Co — 12.03%
- Johnson & Johnson — 6.75%
- Merck & Co Inc — 6.00%
- UnitedHealth Group Inc — 4.74%
- AbbVie Inc — 4.21%
- Elevance Health Inc — 3.00%
- Intuitive Surgical Inc — 2.88%
- CVS Health Corp — 2.84%
- Vertex Pharmaceuticals Inc — 2.64%
- Danaher Corp — 2.57%
FAQ
What is the difference between PRHSX and HGHAX?
Which is cheaper, PRHSX or HGHAX?
Should I own both PRHSX and HGHAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.